Fetuin‐A aggravates lipotoxicity in podocytes via interleukin‐1 signaling

Physiological Reports

Friederike Schulze¹  Kapil Kampe²  Jonas Sieber²  Jana M. Orellana²  Andreas W. Jehle² 

[1] Department of Biomedicine, Diabetes Research University Hospital Basel Switzerland;Department of Biomedicine, Molecular Nephrology University Hospital Basel Switzerland;

关键词: Diabetic nephropathy;    Fetuin‐A;    free fatty acids;    interleukin‐1;    palmitic acid;    toll‐like receptor;   

DOI  :  10.14814/phy2.13287

来源: DOAJ

【 摘 要 】

Abstract Sterile inflammation is considered critical in the pathogenesis of diabetic nephropathy (DN). Here we show that Fetuin‐A (FetA) or lipopolysaccharide (LPS) exacerbate palmitic acid‐induced podocyte death, which is associated with a strong induction of monocyte chemoattractant protein‐1 (MCP‐1) and keratinocyte chemoattractant (KC). Moreover, blockage of TLR4 prevents MCP‐1 and KC secretion and attenuates podocyte death induced by palmitic acid alone or combined with FetA. In addition, inhibition of interleukin‐1 (IL‐1) signaling by anakinra, a recombinant human IL‐1Ra, or a murinized anti‐IL‐1β antibody attenuates the inflammatory and ultimate cell death response elicited by FetA alone or combined with palmitic acid. In vivo short‐term therapy of diabetic DBA/2J mice with an anti‐IL1‐β antibody for 4 weeks prevented an increase in serum FetA and considerably decreased urinary tumor necrosis alpha (TNF‐α), a known risk factor for DN progression. In summary, our results suggest that FetA similarly to LPS leads to an inflammatory response in podocytes, which exacerbates palmitic acid‐induced podocyte death and our data imply a critical role for IL‐1β signaling in this process. The study offers the rational for prolonged in vivo studies aimed at testing anti‐IL‐1β therapy for prevention and treatment of DN.

【 授权许可】

Unknown